Lv3
212 积分 2024-01-18 加入
Phase II Trial of Weekly Single-Agent Paclitaxel in Platinum/Paclitaxel-Refractory Ovarian Cancer
20小时前
已完结
A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a gynecologic oncology group study
13天前
已完结
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study
13天前
已完结
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
13天前
已完结
Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer
14天前
已完结
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study
14天前
已完结
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
14天前
已完结
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance
15天前
已完结
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
21天前
已完结
Mocertatug rezetecan, a B7-H4-targeted antibody-drug conjugate, in combination with bevacizumab in patients with platinum-sensitive ovarian cancer: results from a phase 1 study
1个月前
已关闭
皖公网安备34019202002308
